Nicole Rich, MD

Articles

Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023

April 10th 2023

Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.

Management of Child-Pugh B Patients with Advanced HCC

April 3rd 2023

Oncologists provide an overview of the treatment management of Child-Pugh B patients with advanced HCC.

Treatment Considerations for Advanced HCC in Second Line and Beyond

April 3rd 2023

In this discussion, panelists outline treatment considerations for patients with advanced HCC in the 2L setting and beyond.

Systemic Immunotherapies for Advanced HCC in Second Line and Beyond

March 27th 2023

In the context of frontline treatment strategies in advanced HCC, expert oncologists review clinical research in systemic immunotherapy approaches.

Anti-Angiogenic Systemic Therapies for Advanced HCC in Second Line and Beyond

March 27th 2023

Expert panelists highlight anti-angiogenic systemic therapies under investigation for advanced HCC in second line and beyond.

Patient Profile 3: Advanced HCC Treatment in Second Line and Beyond

March 20th 2023

Oncologists review a patient profile, evaluating treatment approaches for patients with advanced HCC that have progressed beyond 1L treatment.

Treatment Selection in Patients Unsuitable for Atezolizumab + Bevacizumab

March 20th 2023

Experts discuss treatment options for patients unsuitable for atezolizumab plus bevacizumab in advanced hepatocellular carcinoma.

Real-World Evidence for Lenvatinib in Advanced HCC

March 13th 2023

Panelists share real-world evidence involving the use of lenvatinib in advanced HCC.

Patient Profile 2: Advanced HCC Treated with Lenvatinib

March 13th 2023

A panel of oncologists review a patient profile, evaluating a patient with advanced HCC treated with lenvatinib.

Other Frontline Immunotherapy-based Combinations in Advanced HCC

March 6th 2023

Expert oncologists analyze immunotherapy-based combinations in the frontline setting for patients with hepatocellular carcinoma.

Selecting the Appropriate Frontline Treatment in Advanced HCC

March 6th 2023

Experts discuss the factors they take into consideration when selecting the appropriate treatment in advanced HCC.

HIMALAYA Study: Durvalumab + Tremelimumab in First-Line Treatment of Advanced HCC

February 20th 2023

Panelists review the HIMALAYA study, investigating durvalumab plus tremelimumab in patients with advanced HCC.

Patient Profile 1: Advanced HCC Treated with Durvalumab + Tremelimumab

February 20th 2023

Expert oncologists discuss a patient profile in advanced HCC, evaluating a patient treated with durvalumab plus tremelimumab.

Patients With Intermediate Stage HCC Suitable for TACE

February 20th 2023

Experts review clinical studies evaluating TACE in patients with intermediate stage HCC.

Patients With Intermediate Stage HCC Unsuitable for TACE

February 20th 2023

Expert panelists discuss treatment strategies for patients with intermediate stage hepatocellular carcinoma (HCC) that are unsuitable for transarterial chemoembolization (TACE).

Patient Case: 63-Year-Old Woman With Advanced HCC

April 20th 2022

Drs Anthony B. El-Khoueiry, Daneng Li, Nicole Rich, and Pierre Gholam share treatment approaches for a 63-year-old woman who received an advanced HCC diagnosis with Child-Pugh A liver function.

How the Potential Use of Immunotherapy in Intermediate HCC Might Affect its Use in Advanced HCC

April 20th 2022

Dr Nicole Rich discusses immunotherapy and potential combinations in intermediate and advanced hepatocellular carcinoma.

Unmet Needs in the Treatment of Advanced HCC in Second-Line and Beyond

April 20th 2022

Key opinion leaders in gastrointestinal cancers provide insight on unmet needs and challenges in the treatment of advanced hepatocellular carcinoma in the second-line and beyond setting.

Sequencing Therapies After Frontline TKI Therapy in Advanced HCC

April 13th 2022

Experts in gastrointestinal cancers comment on their treatment approaches for patients with second-line advanced hepatocellular carcinoma who receive frontline TKI therapy.

Selecting the Appropriate Treatment in Second-Line and Beyond in Advanced HCC

April 13th 2022

Experts in gastrointestinal cancers share factors to consider when selecting the optimal second-line therapy for patients with advanced hepatocellular carcinoma.